NOVATO, Calif., March 29, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced its participation as a presenting company at the 20th Annual Future Leaders in the Biotech Industry Conference on April 5, 2013. Shalini Sharp, the company's Chief Financial Officer, is scheduled to present at 11:30am Eastern Time in Room 508 at the Millennium Broadway Hotel in New York.
About Ultragenyx
Ultragenyx is a privately held, development-stage biotechnology company committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases. The company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no effective treatments.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx' strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.